SCHEMBL25196397

SCHEMBL25196397

C=C(OCC)c1ccc(C(N)=O)nc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.42
MAPK1 P28482 2/20 0.41
NNMT P40261 4/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
P4HTM Q9NXG6 3/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39
DGAT1 O75907 1/20 0.39
VNN1 O95497 1/20 0.39
P4HA1 P13674 1/20 0.39
MIF P14174 1/20 0.39
SIRT6 Q8N6T7 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2108606 0.86 P4HTM (0.56) MAPK1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL2109944 0.86 MAPK1 (0.50) MAPK1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL1004608 0.84 MAPK1 (0.64) MAPK1L3MBTL1MAPTKDM4EP4HTM
SCHEMBL24775612 0.78 MAPK1 (0.64) MAPK1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL7713081 0.77 DGAT1 (0.45) KMT2AL3MBTL1MAPTKDM4ECYP1A2
SCHEMBL29601679 0.77 KMT2A (0.40) MAPK1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL27039749 0.77 KMT2A (0.40) MAPK1KMT2AL3MBTL1MAPTKDM4E
SCHEMBL22531098 0.77 RAB9A (0.43) MAPK1KMT2AL3MBTL1MAPTP4HTM
SCHEMBL22531099 0.77 RAB9A (0.43) MAPK1KMT2AL3MBTL1MAPTP4HTM
SCHEMBL29388906 0.77 RAB9A (0.43) MAPK1KMT2AL3MBTL1MAPTP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116134035-B 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2025-03-11 CN disclosed
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS JANSSEN RESEARCH & DEVELOPMENT, LLC 2023-09-21 US disclosed
EP-4185588-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS Janssen Pharmaceutica NV (BE) 2023-05-31 EP disclosed
CN-116134035-A 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2023-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS SERPINC1, F11, TFPI2 PARP10 1604/4885MAPK1 2000/4885NNMT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.